Barrett's Esophagus Risk Scoring With Multiplex Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting the progression of Barrett's esophagus to esophageal adenocarcinoma are limited by inter-observer variation in histologic evaluation and the lack of reliable biomarkers for risk prediction, making it difficult to identify patients at high risk for progression and requiring ineffective surveillance frequencies.
Innovation Solution
A tissue systems pathology approach using multiplexed fluorescence biomarker labeling and digital imaging to quantify multiple epithelial and stromal biomarkers, integrated with a multivariable classifier to generate a prognostic score for predicting the risk of progression to high-grade dysplasia or esophageal adenocarcinoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If histologic evaluation of esophageal biopsies is performed to detect dysplasia, then diagnosis can be made, but inter-observer variation and random endoscopic sampling limit measurement precision
Solution Approach 1:
The patent replaces manual histologic evaluation with automated digital image analysis and AI-based classification systems. Whole slide imaging captures complete tissue architecture, and computer algorithms objectively quantify morphometric features, eliminating inter-observer variation and providing consistent, reproducible dysplasia diagnoses across different pathologists and institutions.
Solution Approach 2:
The patent employs a multi-parameter classification system that simultaneously evaluates multiple morphometric features (nuclear size, shape, chromatin pattern, glandular architecture) to make a unified dysplasia diagnosis. This comprehensive approach provides a universal diagnostic framework that can be applied consistently across different cases and pathologists, improving both precision and reliability.
2Measurement precision
If endoscopic surveillance with biopsies is performed at frequent intervals, then early detection of dysplasia is improved, but the complexity and cost of management increases
Solution Approach 1:
The patent applies advanced image analysis and AI classification to baseline biopsy samples to identify patients at highest risk for progression to dysplasia and cancer. This preliminary risk stratification allows clinicians to prioritize intensive surveillance for high-risk patients while reducing surveillance frequency for low-risk patients, optimizing resource allocation and reducing overall program complexity.
Solution Approach 2:
The patent implements risk-stratified surveillance where the intensity and frequency of monitoring are tailored to individual patient risk profiles. High-risk patients receive more frequent and detailed evaluation, while low-risk patients undergo less intensive surveillance, creating a customized management approach that improves early detection efficiency without uniformly increasing program complexity for all patients.
3Measurement precision
If multiple biomarkers are evaluated to predict progression risk, then risk prediction accuracy is improved, but the complexity of the test system increases
Solution Approach 1:
The patent integrates multiple morphometric parameters (nuclear area, nuclear-to-cytoplasmic ratio, chromatin density, glandular architecture, cellular orientation) into a unified AI-based classification model. This merging of multiple features into a single comprehensive risk assessment simplifies the clinical workflow while maintaining high prediction accuracy, as the system processes all parameters simultaneously through automated image analysis.
Solution Approach 2:
The patent transforms complex multi-parameter biomarker data into simplified risk categories (low, intermediate, high risk) through AI classification. This parameter transformation maintains the predictive power of multiple biomarkers while presenting results in an easily interpretable format that reduces clinical decision complexity and facilitates straightforward patient management.
Data Source
AI summary
Embodiments described herein provide methods of determining a risk of progression of Barrett's esophagus in a subject, classifying Barrett's esophagus in a subject and detecting a field effect associated with malignant transformation of an esophagus of a subject suffering from Barrett's esophagus. The disclosure also provides kits for determining a risk of progression of Barrett's esophagus in a subject and classifying Barrett's esophagus in a subject.